Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers

Clinical Pharmacology Program, Addiction Research Foundation Clinical Institute, Toronto, Ontario, Canada.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.9). 05/1990; 47(4):490-8. DOI: 10.1038/clpt.1990.62
Source: PubMed


The effects of fluoxetine, a relatively selective long-acting serotonin uptake inhibitor, on the consumption of alcoholic and nonalcoholic drinks, cigarette smoking, and body weight were assessed in 29 men who were early stage problem drinkers. After a 2-week baseline, subjects were randomly assigned to receive 40 mg/day fluoxetine (n = 8), 60 mg/day fluoxetine (n = 11), or placebo (n = 10) for 4 weeks. Fluoxetine 60 mg/day decreased mean daily alcoholic drinks from (X +/- SEM) 8.3 +/- 0.7 during baseline to 6.9 +/- 0.7 and decreased total drinks per 14 days from 115.8 +/- 9.3 to 96.5 +/- 9.5 (p less than 0.01; 17.3% decrease from baseline), with no significant increase in days of abstinence. Neither 40 mg/day fluoxetine nor placebo had effects on intake of alcohol. Fluoxetine 60 mg/day decreased total and mean daily alcoholic drinks compared with 40 mg/day fluoxetine (ANCOVA, both p less than 0.02), but neither dose of fluoxetine was different from placebo. Compared with placebo, both 40 mg/day fluoxetine and 60 mg/day fluoxetine no differences were detected between treatment groups, 60 mg/day fluoxetine increased mean daily nonalcoholic beverages from baseline (5.0 +/- 0.4 to 5.6 +/- 0.3, p less than 0.01) and increased daily cigarettes smoked (from 25.1 +/- 4.6 to 26.9 +/- 4.5, p less than 0.05), whereas no significant changes from baseline were observed with 40 mg/day fluoxetine or placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text


Available from: Edward M Sellers, Jul 04, 2014
21 Reads
  • Source
    • "Fluoxetine lacks consistent evidence for its usefulness in alcohol dependence. In undiagnosed alcohol-dependent patients, 60 mg daily of fluoxetine reduced total and daily drinks80 and significantly reduced craving compared to baseline, but not to placebo;81 however, 60 mg did not affect abstinence80 or relapse rates in very heavy drinkers (average 18.6 drinks/day),82 nor reduce daily baseline or drinks per drinking day when compared to placebo.81 When dosed at 40 mg, fluoxetine did not reduce intake levels.80 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alcohol use disorders (AUD) continue to be a concerning health issue worldwide. Harmful alcohol use leads to 2.5 million deaths annually worldwide. Multiple options exist for the management of dependence on alcohol, not all of which are approved by drug-regulating agencies. Current practice in treating AUD does not reflect the diversity of pharmacologic options that have potential to provide benefit, and guidance for clinicians is limited. Few medications are approved for treatment of AUD, and these have exhibited small and/or inconsistent effects in broad patient populations with diverse drinking patterns. The need for continued research into the treatment of this disease is evident in order to provide patients with more specific and effective options. This review describes the neurobiological mechanisms of AUD that are amenable to treatment and drug therapies that target pathophysiological conditions of AUD to reduce drinking. In addition, current literature on pharmacologic (both approved and non-approved) treatment options for AUD offered in the United States and elsewhere are reviewed. The aim is to inform clinicians regarding the options for alcohol abuse treatment, keeping in mind that not all treatments are completely successful in reducing craving or heavy drinking or increasing abstinence.
    01/2014; 5:1-12. DOI:10.2147/SAR.S37907
  • Source
    • "A number of laboratory based studies with rats demonstrated that administration of selective serotonin reagents reduced alcohol consumption by up to 84% [106] [107]. These findings led a number of researchers to propose that the SSRIs may be an effective adjunct to treatment for alcohol dependence and comorbid depression [108] [109]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Among the numerous forms of comorbid mental health and substance use disorders, co-morbidity between alcohol use disorders (AUD) and depression has received considerable attention. AUDs and depression co-occur at levels greater than expected by chance in clinical and epidemiological samples. Studies suggest that about 80% of patients with AUD experience depressive symptoms at some stage in their lives including 30% or more who describe significant depression which lasts for weeks and which meets criteria for a major depressive episode. Several hypotheses have been proposed to explain why the two disorders co-occur in individuals at higher than expected rates. There is also emerging evidence to suggest that pharmacological treatment of depressive symptomatology as an adjunct to treatment for alcohol dependence may be effective not only in treating depression but also in reducing alcohol consumption and alcohol related harm. This review explores the literature on the epidemiology, etiology and management of depression and co-morbid AUD. It also identifies the areas for further research.
    Current Psychiatry Reviews 11/2013; 9(4):271-283. DOI:10.2174/15734005113096660005
  • Source
    • "Moreover, the existence of an inverse relationship between brain 5-HT tone and alcohol consumption has been repeatedly reported in the literature. Drugs that increase extracellular 5-HT levels, such as selective serotonin reuptake inhibitors (SSRIs) (Borg et al. 1985; Naranjo et al. 1990; LeMarquand et al. 1994; Maurel et al. 1999), reduce ethanol intake in animal models of alcoholism, while low brain 5-HT levels correlate with high ethanol intake (Murphy et al. 1982; Higley et al. 1996). Furthermore, in serotonin transporter (5-HTT) knock-out mice, permanent inactivation of the 5-HTT was found to be associated with both enhanced extracellular 5-HT levels in brain (Fabre et al. 2000) and reduced alcohol intake (Kelai et al. 2003) compared to paired wild-type mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Because cannabinoid and serotonin (5-HT) systems have been proposed to play an important role in drug craving, we investigated whether cannabinoid 1 (CB1) and 5-HT(1A) receptor ligands could affect voluntary alcohol intake in two mouse strains, C57BL/6 J and DBA/2 J, with marked differences in native alcohol preference. When offered progressively (3-10% ethanol) in drinking water, in a free-choice procedure, alcohol intake was markedly lower (approximately 70%) in DBA/2 J than in C57BL/6 J mice. In DBA/2 J mice, chronic treatment with the cannabinoid receptor agonist WIN 55,212-2 increased alcohol intake. WIN 55,212-2 effect was prevented by concomitant, chronic CB1 receptor blockade by rimonabant or chronic 5-HT(1A) receptor stimulation by 8-hydroxy-2-(di-n-propylamino)-tetralin, which, on their own, did not affect alcohol intake. In C57BL/6 J mice, chronic treatment with WIN 55,212-2 had no effect but chronic CB1 receptor blockade or chronic 5-HT(1A) receptor stimulation significantly decreased alcohol intake. Parallel autoradiographic investigations showed that chronic treatment with WIN 55,212-2 significantly decreased 5-HT(1A)-mediated [35S]guanosine triphosphate-gamma-S binding in the hippocampus of both mouse strains. Conversely, chronic rimonabant increased this binding in C57BL/6 J mice. These results show that cannabinoid neurotransmission can exert a permissive control on alcohol intake, possibly through CB1-5-HT(1A) interactions. However, the differences between C57BL/6 J and DBA/2 J mice indicate that such modulations of alcohol intake are under genetic control.
    Journal of Neurochemistry 11/2006; 99(1):308-20. DOI:10.1111/j.1471-4159.2006.04054.x · 4.28 Impact Factor
Show more